CARDIAMP CMI Cohort Results -- In the open-label rolling cohort (n=5), patients saw an average 80-second increase in exercise ...

Revised 2025 Guidance -- Projected cell processing revenue of $93 million to $94 million, representing 26%-28% growth; total ...

Q3 2025 Earnings Call Transcript November 14, 2025 MiNK Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Q3 2025 Earnings Call Transcript November 13, 2025 zSpace, Inc. misses on earnings expectations. Reported EPS is $-0.26 EPS, expectations were $-0.2. Operator: Hello, and thank you for participating ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

Enovis’ third quarter results surpassed Wall Street’s revenue and non-GAAP profit expectations, but the market reacted ...

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look ...

Fate Therapeutics Inc. FATE) on Thursday reported a loss of $32.3 million in its third quarter. The San Diego-based company said it had a loss of 27 cents per share.

Q3 2025 Earnings Call November 13, 2025 5:00 PM ESTCompany ParticipantsPaul Kellenberger - CEO & ChairpersonErick DeOliveira - ...

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q3 2025 Earnings Call Transcript November 12, 2025 Atea Pharmaceuticals, Inc.

Detailed price information for Bank of New York Mellon Corp (BK-N) from The Globe and Mail including charting and trades.

PDS Biotechnology Corporation (NASDAQ: PDSB) Q3 2025 Earnings Call Transcript November 13, 2025 ...